1B1E827B-A98A-465E-AC6F-448C076E829D
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- overall_survival_months
- 18.758212877792378
- age_years
- 50
- sex
- Male
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- INTERFERON_ALPHA_RESPONSE+0.689
- INTERFERON_GAMMA_RESPONSE+0.674
- TNFA_SIGNALING_VIA_NFKB+0.540
- IL6_JAK_STAT3_SIGNALING+0.498
- ALLOGRAFT_REJECTION+0.455
- MYC_TARGETS_V2+0.450
- MTORC1_SIGNALING+0.428
- REACTIVE_OXYGEN_SPECIES_PATHWAY+0.423
- TGF_BETA_SIGNALING+0.419
- DNA_REPAIR+0.414
Top 10 suppressed
- KRAS_SIGNALING_DN-0.432
- SPERMATOGENESIS-0.359
- PANCREAS_BETA_CELLS-0.350
- MYOGENESIS-0.154
- APICAL_SURFACE-0.049
- BILE_ACID_METABOLISM-0.040
- ESTROGEN_RESPONSE_LATE+0.024
- HEDGEHOG_SIGNALING+0.027
- UV_RESPONSE_DN+0.049
- FATTY_ACID_METABOLISM+0.105
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | C33EDB64-C7B9-49A1-AE73-1D293F8522F6 | — | — | 0.972 |
| 2 | 7876A884-F031-42AB-ADC0-89589760FB6B | — | — | 0.971 |
| 3 | A678E1E5-E02D-49A1-BB2B-C91A60E6382E | — | — | 0.970 |
| 4 | DE370889-1057-4355-AFD8-CCFCDC6CD00F | — | — | 0.967 |
| 5 | SRR934921 | — | — | 0.966 |
| 6 | F9A39954-57EB-4A3F-97A0-1801B08BBD53 | — | — | 0.960 |
| 7 | SRR934874 | — | — | 0.959 |
| 8 | 44B1F003-553A-4C8A-A6AE-44C49262081C | — | — | 0.959 |
| 9 | A9B59C46-7F32-4DD1-9649-B1788CA5E909 | — | — | 0.957 |
| 10 | 0E66EFB0-712B-4A52-8F75-A37F030CABEF | — | — | 0.957 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 44 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| INTERFERON_ALPHA_RESPONSE | 0.689 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.674 | Idelalisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.540 | Inavolisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.498 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.455 | Idelalisib | — uncovered |
| MYC_TARGETS_V2 | 0.450 | Idelalisib | — uncovered |
| MTORC1_SIGNALING | 0.428 | Inavolisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.423 | Inavolisib | — uncovered |
| TGF_BETA_SIGNALING | 0.419 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.414 | Idelalisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.414 | Idelalisib | — uncovered |
| MYC_TARGETS_V1 | 0.409 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.403 | Idelalisib | — uncovered |
| ANDROGEN_RESPONSE | 0.388 | Inavolisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.382 | Idelalisib | — uncovered |
| ANGIOGENESIS | 0.380 | Remibrutinib | — uncovered |
| APOPTOSIS | 0.373 | Idelalisib | — uncovered |
| HYPOXIA | 0.371 | Idelalisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.369 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.357 | Remibrutinib | — uncovered |